Experienced in ABO Incompatibility

Hiroshi Sakai

Hiroshima, JP 
Experienced in ABO Incompatibility
Hiroshima, JP 
OverviewLocationsClinical Research

Overview

Hiroshi Sakai practices in Hiroshima, Japan. Mr. Sakai is rated as an Experienced expert by MediFind in the treatment of ABO Incompatibility. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Glaucoma, Tissue Biopsy, and Hepatectomy.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of ABO Incompatibility.

Gender
Male

Locations

Hiroshima, Japan
Other Locations
Toon, 7910295, Japan
Hachioji, 1920397, Japan
7910295, Japan
Urasoe, Japan
Urazoe, Japan
Minami, 7348551, Japan
Ageoshimo, Japan
Saitama, Japan
Osaka, Japan
Tsukuba, 3050801, Japan
Komuro, 3620806, Japan
Matsumoto, Japan
Ina, Japan
Kitakyushu, 8020077, Japan
Kita, 3620806, Japan
Naha, Japan
Tokyo, Japan
Yonashiro-nishihara, Japan
Okinawa, Japan
Nishihara, Japan
Hongo, 1138656, Japan
Hidaka, Japan
Kawahara, 6068507, Japan
Kyoto, Japan
Fukuoka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
View 2 Less Clinical Trials

198 Total Publications

Successful Treatment of Median Arcuate Ligament Syndrome in the Hybrid Operating Room: A Report of Four Cases.
Successful Treatment of Median Arcuate Ligament Syndrome in the Hybrid Operating Room: A Report of Four Cases.
Journal: Cureus
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sakai's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile